Toboroz
A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.
NCT07734116· 1/2. fázis· Ono Pharmaceutical Co., Ltd.· Forrás
Contact: North America Clinical Trial Support Desk
Még nem toboroz
Breakthrough Platform Trial for PCAS
NCT07769086· Kagawa University· Forrás
Contact: Tetsuya Yumoto
Toboroz
Long-term Safety Study Following to JRM-001 Treatment in Pediatric Patients With Congenital Heart Disease
NCT07884318· Metcela Inc.· Forrás
Contact: Okayama University Hospital
Toboroz
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
NCT07783425· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
NCT07596849· 3. fázis· argenx· Forrás
Contact: Tomohiro Terasaka
Toboroz
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
NCT07623616· 2. fázis· Kyowa Kirin Co., Ltd.· Forrás
Contact: Kyowa Kirin, Inc.
Toboroz
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270· 3. fázis· Genmab· Forrás
Toboroz
A Study of E6742 in Participants With Systemic Lupus Erythematosus
NCT07515014· 2. fázis· Eisai Co., Ltd.· Forrás
Toboroz
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044· 2. fázis· Eli Lilly and Company· Forrás
Contact: Toshihiro Inokuchi (principal investigator)
Toboroz
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Eiki Ichihara, Site 0907
Toboroz
MSA-01 in Multiple System Atrophy
NCT07446894· 3. fázis· Tokyo University· Forrás
Contact: Hiroyuki Ishiura
Toboroz
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199· 3. fázis· Taiho Oncology, Inc.· Forrás
Contact: Taiho Oncology, Inc.
Fut, nem toboroz
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· 3. fázis· Incyte Corporation· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173· 2. fázis· Eli Lilly and Company· Forrás
Contact: Nobuaki Miyahara (principal investigator)
Toboroz
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· 3. fázis· Eli Lilly and Company· Forrás
Contact: Shoji Nagao (principal investigator)
Toboroz
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· 3. fázis· Eli Lilly and Company· Forrás
Contact: Miwa Kawanaka (principal investigator)
Toboroz
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275· 2/3. fázis· Vertex Pharmaceuticals Incorporated· Forrás
Toboroz
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
NCT07022483· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· 3. fázis· BeOne Medicines· Forrás
Contact: Study Director
Fut, nem toboroz
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128· 3. fázis· Amgen· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· 3. fázis· Pfizer· Forrás
Toboroz
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109· 3. fázis· Nuvalent Inc.· Forrás
Contact: Kiichiro Ninomiya, MD (principal investigator)
Fut, nem toboroz
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT07015983· 2. fázis· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Forrás
Toboroz
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
NCT06976944· 2. fázis· Yukinori Ozaki· Forrás
Contact: Yuko Takahashi
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
NCT06882785· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Shinji Sakamoto, Site 0055
Fut, nem toboroz
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125· 3. fázis· Stoke Therapeutics, Inc· Forrás
Toboroz
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834· 3. fázis· Gilead Sciences· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· 3. fázis· NRG Oncology· Forrás
Contact: Shoji Nagao (principal investigator)
Meghívásos bevonás
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226· 3. fázis· Longboard Pharmaceuticals· Forrás
Fut, nem toboroz
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· 3. fázis· Genmab· Forrás
Toboroz
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355· 3. fázis· BioNTech SE· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· 3. fázis· Alumis Inc· Forrás
Fut, nem toboroz
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· 3. fázis· Pfizer· Forrás
Toboroz
Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest
NCT06776549· Kagawa University· Forrás
Contact: Tetsuya Yumoto (principal investigator)
Meghívásos bevonás
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
NCT06723106· 1. fázis· Chugai Pharmaceutical· Forrás
Fut, nem toboroz
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· 3. fázis· Genmab· Forrás
Toboroz
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Fut, nem toboroz
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141· 3. fázis· Longboard Pharmaceuticals· Forrás
Toboroz
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.
NCT06812104· 1. fázis· Kyowa Kirin Co., Ltd.· Forrás
Contact: Masayoshi Noshiro
Toboroz
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
NCT06598306· 1. fázis· Amgen· Forrás
Fut, nem toboroz
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394· 3. fázis· Longboard Pharmaceuticals· Forrás
Fut, nem toboroz
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441· 3. fázis· Gilead Sciences· Forrás
Showing 50 of 126.